ReviewCurrent treatment options in gastroenterology2018
Management of Intraductal Papillary Mucinous Neoplasms: Controversies in Guidelines and Future Perspectives.
Review in Current treatment options in gastroenterology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06574373 (New Theranostic Biomarkers of Intraductal Mucinous Neoplasm), which is not on this map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
New Theranostic Biomarkers of Intraductal Mucinous Neoplasm (IPMN) Progression to Pancreatic Cancer for Patients' Outcome Improvement
Who cites it
25 citing papers in PubMed.
- Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas: History, Myths, and Realities Between Past and Future.Medical sciences (Basel, Switzerland) · 2026Review
- Pancreatic Cystic Lesions: From Basic Knowledge to Recent Guidelines.Journal of clinical medicine · 2026Review
- Quintuple Primary Cancers Including Intraductal Papillary Mucinous Carcinoma: A Case Report.Surgical case reports · 2026Article
- Cystic tumors of the pancreas: Current perspectives on diagnosis and management.World journal of gastroenterology · 2025Review
- Comprehensive insights into pancreatic cancer treatment approaches and cutting-edge nanocarrier solutions: from pathology to nanomedicine.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Current Considerations in Nonoperative Surveillance of Intraductal Papillary Mucinous Neoplasms.Digestive disease interventions · 2025Article
- Advances for Managing Pancreatic Cystic Lesions: Integrating Imaging and AI Innovations.Cancers · 2024Review
- Pancreatic Cancer: A Review of Risk Factors.Life (Basel, Switzerland) · 2024Review
- Novel Insights into Postoperative Surveillance in Resected Pancreatic Cystic Neoplasms-A Review.Diagnostics (Basel, Switzerland) · 2024Review
- Identification of spatially-resolved markers of malignant transformation in Intraductal Papillary Mucinous Neoplasms.Nature communications · 2024Article
- Long-term surveillance of branch-duct intraductal papillary mucinous neoplasms without worrisome or high-risk features.Journal of surgical oncology · 2023Observational
- Real-Life Management of Pancreatic Cysts: Simplified Review of Current Guidelines.Journal of clinical medicine · 2023Review
- Intracystic papillary neoplasm diagnosis following an extended cholecystectomy: a case report … and literature review.Oxford medical case reports · 2023Article
- Endoscopic Ultrasound-Guided Local Ablative Therapies for the Treatment of Pancreatic Neuroendocrine Tumors and Cystic Lesions: A Review of the Current Literature.Journal of clinical medicine · 2023Review
- Article
- Peritoneal Metastases After Intraductal Papillary Mucinous Neoplasm Resection: How Common are They?The Journal of surgical research · 2023Review
- Risk Assessment and Pancreatic Cancer: Diagnostic Management and Artificial Intelligence.Cancers · 2023Review
- Pancreatic Intraductal Papillary Mucinous Neoplasms: A Narrative Review.Acta medica Lituanic · 2023Review
- Natural history of intracholecystic papillary neoplasm (ICPN): a rare case of ICPN whose natural history was closely followed by ultrasound.BMC gastroenterology · 2022Article
- SupplementalCancers · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewManagement of intraductal papillary mucinous neoplasm (IPMN) is currently based on consensus, in the absence of evidence-based guidelines. In recent years, several consensus guidelines have been published, with distinct management strategies. In this review, we will discuss these discrepancies, in order to guide treating physicians in clinical management. RECENT
findingsThe detection rate of pancreatic cysts has increased substantially with the expanded use of high-quality imaging techniques to up to 45%. Of these cysts, 24-82% are IPMNs, which harbour a malignant potential. Timely detection of high-risk lesions is therefore of great importance. Surgical management is based on the presence of clinical and morphological high-risk features, yet the majority of resected specimens appear to be low risk. International collaboration and incentive large-scale prospective registries of individuals undergoing cyst surveillance are needed to accumulate unbiased data and develop evidence-based guidelines. Additionally, development of non-invasive, accurate diagnostic tools (e.g. biomarkers) is needed to differentiate between neoplastic and non-neoplastic pancreatic cysts and detect malignant transformation at an early stage (i.e. high-grade dysplasia).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.